| pubmed-article:18505779 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18505779 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:18505779 | lifeskim:mentions | umls-concept:C0016693 | lld:lifeskim |
| pubmed-article:18505779 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:18505779 | lifeskim:mentions | umls-concept:C0289884 | lld:lifeskim |
| pubmed-article:18505779 | lifeskim:mentions | umls-concept:C0301630 | lld:lifeskim |
| pubmed-article:18505779 | lifeskim:mentions | umls-concept:C0528175 | lld:lifeskim |
| pubmed-article:18505779 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:18505779 | pubmed:dateCreated | 2008-7-9 | lld:pubmed |
| pubmed-article:18505779 | pubmed:abstractText | Free radicals have been found in high concentrations within inflammatory multiple sclerosis (MS) lesions. The superoxide anion (O(2)(-)) reacts rapidly with nitric oxide (NO), producing peroxynitrite (ONOO(-)). Glatiramer acetate (GA) is a specific MS immunomodulator that induces the synthesis of Th2 cytokines, and reduces the frequency of relapses and the formation of active brain lesions. Proinflammatory cytokines could play a role in free radicals production in the peripheral immune system as well as in the central nervous system (CNS). The effect of GA on iNOS, superoxide radicals (O(2)(-)) and 3-nitrotyrosine production by peripheral blood adherent mononuclear cells (PBAMs) was assessed. Our findings demonstrate that in vitro GA reduced spontaneous and LPS-induced iNOS, 3-nitrotyrosine, NO and O(2)(-) production, and that similar inhibition can be demonstrated ex vivo in mononuclear cells obtained from GA-treated patients. The inhibition of the production of free radicals in PBAMs may represent a new therapeutic mechanism against inflammation during MS. | lld:pubmed |
| pubmed-article:18505779 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18505779 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18505779 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18505779 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18505779 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18505779 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18505779 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18505779 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18505779 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18505779 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18505779 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18505779 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18505779 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18505779 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18505779 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18505779 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:18505779 | pubmed:issn | 1352-4585 | lld:pubmed |
| pubmed-article:18505779 | pubmed:author | pubmed-author:GambiDD | lld:pubmed |
| pubmed-article:18505779 | pubmed:author | pubmed-author:RealeMM | lld:pubmed |
| pubmed-article:18505779 | pubmed:author | pubmed-author:SalvatoreMM | lld:pubmed |
| pubmed-article:18505779 | pubmed:author | pubmed-author:FelacoMM | lld:pubmed |
| pubmed-article:18505779 | pubmed:author | pubmed-author:LugaresiAA | lld:pubmed |
| pubmed-article:18505779 | pubmed:author | pubmed-author:PatrunoAA | lld:pubmed |
| pubmed-article:18505779 | pubmed:author | pubmed-author:IarloriCC | lld:pubmed |
| pubmed-article:18505779 | pubmed:author | pubmed-author:SperanzaLL | lld:pubmed |
| pubmed-article:18505779 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18505779 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:18505779 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18505779 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18505779 | pubmed:pagination | 739-48 | lld:pubmed |
| pubmed-article:18505779 | pubmed:dateRevised | 2011-10-27 | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:meshHeading | pubmed-meshheading:18505779... | lld:pubmed |
| pubmed-article:18505779 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18505779 | pubmed:articleTitle | Reduction of free radicals in multiple sclerosis: effect of glatiramer acetate (Copaxone). | lld:pubmed |
| pubmed-article:18505779 | pubmed:affiliation | Department of Oncology and Neuroscience, University G. D'Annunzio, Chieti, Italy. | lld:pubmed |
| pubmed-article:18505779 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18505779 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:18505779 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
